The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...

Novartis said Friday that last year was one of its 'strongest' financial performances in its history following a multiyear ...

Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it ...

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

European shares were at a record high on Friday, led by technology and healthcare stocks, even as caution prevailed ahead of ...

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues. Fourth-quarter ...

Novartis expects profit and sales to grow further this year after beating analysts' expectations in the fourth quarter, boosted by revenue from its key drugs.